Breaking News

INCY

Incyte

02
Jun
14
Jun

05/04/23 JMP Securities: Incyte price target lowered to $93 from $113 at JMP Securities

05/04/23 BofA: Incyte downgraded to Neutral at BofA on long-term value uncertainty

05/04/23 BofA: Incyte downgraded to Neutral from Buy at BofA

05/03/23 BMO Capital: Incyte price target lowered to $70 from $75 at BMO Capital

Clear This Search Refresh Search

Wednesday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Conference/Events	Mizuho biotech analyst to hold an analyst/industry conference call » 09:50 05/24/23 05/24 09:50 05/24/23 09:50 ERAS Erasca $2.96 / -0.03 (-1.00%) , IMRX Immuneering $6.95 / + (+0.00%) , VSTM Verastem / + , MRK Merck $112.88 / -0.42 (-0.37%) , INCY Incyte $64.67 / -0.435 (-0.67%) , EFTR eFfector Therapeutics / + , LPTX Leap Therapeutics / + , RCUS Arcus Biosciences $17.94 / -0.14 (-0.77%) , CRVS Corvus Pharmaceuticals $3.00 / -0.09 (-2.91%) Biotechnology Analyst… Biotechnology Analyst Goldstein, along with Drs. Velcheti and Oberstein discuss targeted therapies in lung and GI cancer, (ERAS, IMRX, VSTM, MRK, INCY, EFTR, LPTX, RCUS, CRVS) as well as emerging trends and themes to be covered at the upcoming ASCO 2023 Annual Meeting on an Analyst/Industry conference call to be held on May 24 at 10 am. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VSTM RCUS MRK LPTX INCY IMRX ERAS EFTR CRVS VSTM Verastem / + 04/26/23 Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO 01/24/23 Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study RCUS Arcus Biosciences $17.94 / -0.14 (-0.77%) 05/15/23 Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead 05/15/23 Expanded Gilead- Arcus pact may result in up to $1B in payments to Arcus 05/15/23 Arcus to receive upfront payment of $35M from Gilead in expanded research pact 12/20/22 Arcus Biosciences falls -30.2% MRK Merck $112.88 / -0.42 (-0.37%) 05/17/23 Immutep announces results from Phse II TACTI-002 trial 05/16/23 Prometheus, Seagen slip after FTC sues to block Horizon acquisition 05/16/23 OncoSec reports Type C meeting with FDA for melanoma treatment 05/15/23 Canadian Solar subsidiary signs aggregation deal for 100MW in Texas LPTX Leap Therapeutics / + 04/12/23 Leap Therapeutics completes enrollment in Part A of DeFianCe study of DKN-01 03/16/23 Leap Therapeutics provides update on BeiGene option agreement for DKN-01 01/17/23 Leap Therapeutics acquires Flame Biosciences INCY Incyte $64.67 / -0.435 (-0.67%) 05/02/23 Incyte tightens Jakafi net product revenues view $2.55B - $2.63B 05/01/23 Incyte says SCRATCH-AD trial meets primary endpoint 04/20/23 Incyte reports EC approval of Opzelura for non-segmental vitiligo repigmentation 04/16/23 MorphoSys, Incyte announce five-year follow-up data from Phase 2 L-MIND study IMRX Immuneering $6.95 / + (+0.00%) 04/18/23 Immuneering down 5% at $11.53 after pricing $30M stock offering 04/18/23 Immuneering announces initial Phase 1 PK, PD, safety data for IMM-1-104 03/28/23 Immuneering appoints Harold Brakewood as CBO 03/05/23 Immuneering presents preclinical data with lead program IMM-1-104 ERAS Erasca $2.96 / -0.03 (-1.00%) 05/16/23 Erasca appoints Davd Chacko as CBO, Nik Chetwyn as COO 05/01/23 Erasca announces U.S. FDA granted FTD to ERAS-801 04/25/23 Erasca announces publication of clinical data on naporafenib 04/18/23 Erasca presents Phase 1b dose escalation data from FLAGSHIP-1 for ERAS-601 EFTR eFfector Therapeutics / + 04/11/23 eFfector Therapeutics to collaborate with Standford Medicine 02/21/23 eFfector announces top-line results from Phase 1b trial of zotatifin 01/05/23 eFfector Therapeutics provides clinical data update for Zotatifin CRVS Corvus Pharmaceuticals $3.00 / -0.09 (-2.91%) 05/17/23 Corvus Pharmaceuticals to present new CPI-818 data at ICML meeting 04/17/23 Corvus Pharmaceuticals presents new data for CPI-818 04/03/23 Corvus Pharmaceuticals announces interim data on CPI-818 02/21/23 Corvus Pharmaceuticals announces new data on CPI-818 ERAS IMRX VSTM MRK INCY EFTR LPTX RCUS CRVS ERAS Erasca $2.96 / -0.03 (-1.00%) 03/29/23 Mizuho Erasca initiated with a Buy at Mizuho 02/24/23 Goldman Sachs Erasca initiated with a Buy at Goldman Sachs 02/03/23 Morgan Stanley Erasca upgraded to Overweight from Equal Weight at Morgan Stanley IMRX Immuneering $6.95 / + (+0.00%) 04/19/23 Mizuho Immuneering upgraded to Buy from Neutral at Mizuho 04/19/23 Morgan Stanley Immuneering upgraded to Equal Weight from Underweight at Morgan Stanley 04/18/23 Chardan Immuneering price target raised to $22 from $18 at Chardan 03/29/23 Mizuho Immuneering initiated with a Neutral at Mizuho VSTM Verastem / + 05/10/23 H.C. Wainwright Verastem price target lowered to $2 from $3 at H.C. Wainwright 03/29/23 Mizuho Verastem initiated with a Neutral at Mizuho 11/07/22 H.C. Wainwright Verastem price target lowered to $3 from $5 at H.C. Wainwright 10/05/22 BTIG Verastem price target lowered to $5 from $8 at BTIG MRK Merck $112.88 / -0.42 (-0.37%) 05/10/23 Jefferies Prometheus downgraded to Hold from Buy at Jefferies 05/01/23 Barclays Merck price target raised to $130 from $128 at Barclays 04/18/23 Wells Fargo Prometheus downgraded to Equal Weight from Overweight at Wells Fargo 04/18/23 RBC Capital Prometheus downgraded to Sector Perform from Outperform at RBC Capital INCY Incyte $64.67 / -0.435 (-0.67%) 05/04/23 JMP Securities Incyte price target lowered to $93 from $113 at JMP Securities 05/04/23 BofA Incyte downgraded to Neutral at BofA on long-term value uncertainty 05/04/23 BofA Incyte downgraded to Neutral from Buy at BofA 05/03/23 BMO Capital Incyte price target lowered to $70 from $75 at BMO Capital EFTR eFfector Therapeutics / + LPTX Leap Therapeutics / + 03/17/23 Piper Sandler Leap Therapeutics news 'disappointing at first glance,' says Piper Sandler 03/17/23 Mizuho Leap Therapeutics price target lowered to $2 from $3 at Mizuho 01/27/23 Mizuho Leap Therapeutics price target lowered to $3 from $6 at Mizuho 01/17/23 Piper Sandler Leap Therapeutics price target lowered to $3 from $4 at Piper Sandler RCUS Arcus Biosciences $17.94 / -0.14 (-0.77%) 03/09/23 Citi Arcus Biosciences price target lowered to $40 from $42 at Citi 12/21/22 Citi Arcus Biosciences selloff a buying opportunity, says Citi 12/21/22 Barclays Arcus Biosciences price target lowered to $36 from $60 at Barclays 12/20/22 Citi Arcus Biosciences price target raised to $42 from $37 at Citi CRVS Corvus Pharmaceuticals $3.00 / -0.09 (-2.91%) 05/09/23 Cantor Fitzgerald Corvus Pharmaceuticals price target raised to $4 from $2 at Cantor Fitzgerald 10/07/22 Ladenburg Corvus Pharmaceuticals initiated with a Buy at Ladenburg 08/09/22 Cantor Fitzgerald Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald VSTM RCUS MRK LPTX INCY ERAS EFTR CRVS VSTM Verastem / + 05/09/23 Verastem reports Q1 EPS (9c), consensus (8c) 03/14/23 Verastem reports Q4 EPS (8c), consensus (10c) RCUS Arcus Biosciences $17.94 / -0.14 (-0.77%) 05/09/23 Arcus Biosciences reports Q1 EPS ($1.09), consensus ($1.16) 02/28/23 Arcus Biosciences reports Q4 EPS (93c), consensus ($1.07) MRK Merck $112.88 / -0.42 (-0.37%) 04/27/23 Merck narrows FY23 revenue view to $57.7B-$58.9B from $57.2B-$58.7B 04/27/23 Merck reports Q1 adjusted EPS $1.40, consensus $1.32 04/26/23 Notable companies reporting before tomorrow's open LPTX Leap Therapeutics / + 05/15/23 Leap Therapeutics reports Q1 EPS (32c), consensus (10c) 03/24/23 Leap Therapeutics reports Q4 EPS (11c), consensus (11c) INCY Incyte $64.67 / -0.435 (-0.67%) 05/02/23 Incyte reports Q1 EPS 37c, consensus 75c 02/07/23 Incyte reports Q4 EPS 62c, consensus 58c 02/06/23 Notable companies reporting before tomorrow's open ERAS Erasca $2.96 / -0.03 (-1.00%) 05/15/23 Erasca reports Q1 EPS (22c), consensus (31c) 03/23/23 Erasca reports Q4 EPS ($1.06) vs. (26c) last year EFTR eFfector Therapeutics / + 05/09/23 eFfector Therapeutics reports Q1 EPS (24c), consensus (14c) 03/08/23 eFfector Therapeutics reports Q4 EPS (22c), consensus (24c) CRVS Corvus Pharmaceuticals $3.00 / -0.09 (-2.91%) 05/08/23 Corvus Pharmaceuticals reports Q1 EPS (17c), consensus (16c) 18 Apr 09 Dec MRK MRK Merck $112.88 / -0.42 (-0.37%) 02/27/23 Pfizer in talks to buy Seagen in deal that may be valued at over $30B, WSJ says 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 01/11/23 Merck, Pfizer rebuff China's efforts to cut Covid drug prices, Bloomberg says 12/30/22 Merck's Covid treatment gets conditional approval in China, Reuters reports VSTM RCUS MRK LPTX INCY ERAS VSTM Verastem / + 03/14/23 Fly Intel: After-Hours Movers RCUS Arcus Biosciences $17.94 / -0.14 (-0.77%) 12/20/22 What You Missed On Wall Street On Tuesday 12/20/22 What You Missed On Wall Street This Morning 12/19/22 Fly Intel: After-Hours Movers 11/30/22 Biotech Alert: Searches spiking for these stocks today MRK Merck $112.88 / -0.42 (-0.37%) 05/16/23 What You Missed On Wall Street On Tuesday 04/27/23 Fly Intel: Pre-market Movers 04/19/23 Biotech Alert: Searches spiking for these stocks today 04/17/23 What You Missed On Wall Street On Monday LPTX Leap Therapeutics / + 05/19/23 Biotech Alert: Searches spiking for these stocks today 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning INCY Incyte $64.67 / -0.435 (-0.67%) 05/05/23 Biotech Alert: Searches spiking for these stocks today 05/04/23 Biotech Alert: Searches spiking for these stocks today 05/02/23 Fly Intel: Pre-market Movers 04/10/23 What You Missed On Wall Street On Monday ERAS Erasca $2.96 / -0.03 (-1.00%) 03/23/23 Fly Intel: After-Hours Movers 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning 05/24/23 Biotechnology 06/02/23 Biotechnology--Pre-ASCO Reception 06/09/23 Biotechnology 06/12/23 Biotech/Biopharma 06/06/23 2023 ASCO Annual Meeting 05/31/23 Verastem - VSTM 08/01/23 Merck - MRK 05/24/23 Immuneering 06/14/23 Incyte Corporation 06/14/23 Immuneering Corp. 06/15/23 Arcus Biosciences, Inc. 06/15/23 Corvus Pharmaceuticals, Inc. 06/16/23 Leap Therapeutics, Inc. 06/22/23 Erasca, Inc. 06/22/23 eFFECTOR Therapeutics Inc MRK MRK Merck $112.88 / -0.42 (-0.37%) 04/25/23 Merck call volume above normal and directionally bullish 04/17/23 Unusually active option classes on open April 17th 03/10/23 Early notable gainers among liquid option names on March 10th 01/10/23 Largest borrow rate increases among liquid names
Conference/Events	Mizuho biotech analyst to hold an analyst/industry conference call » 04:55 05/24/23 05/24 04:55 05/24/23 04:55 ERAS Erasca $3.00 / +0.075 (+2.57%) , IMRX Immuneering $6.95 / -1.23 (-15.04%) , VSTM Verastem / + , MRK Merck $113.28 / -1.175 (-1.03%) , INCY Incyte $65.11 / +0.715 (+1.11%) , EFTR eFfector Therapeutics / + , LPTX Leap Therapeutics / + , RCUS Arcus Biosciences $18.06 / -0.08 (-0.44%) , CRVS Corvus Pharmaceuticals $3.09 / -0.28 (-8.31%) Biotechnology Analyst… Biotechnology Analyst Goldstein, along with Drs. Velcheti and Oberstein discuss targeted therapies in lung and GI cancer, (ERAS, IMRX, VSTM, MRK, INCY, EFTR, LPTX, RCUS, CRVS) as well as emerging trends and themes to be covered at the upcoming ASCO 2023 Annual Meeting on an Analyst/Industry conference call to be held on May 24 at 10 am. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VSTM RCUS MRK LPTX INCY IMRX ERAS EFTR CRVS VSTM Verastem / + 04/26/23 Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO 01/24/23 Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study RCUS Arcus Biosciences $18.06 / -0.08 (-0.44%) 05/15/23 Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead 05/15/23 Expanded Gilead- Arcus pact may result in up to $1B in payments to Arcus 05/15/23 Arcus to receive upfront payment of $35M from Gilead in expanded research pact 12/20/22 Arcus Biosciences falls -30.2% MRK Merck $113.28 / -1.175 (-1.03%) 05/17/23 Immutep announces results from Phse II TACTI-002 trial 05/16/23 Prometheus, Seagen slip after FTC sues to block Horizon acquisition 05/16/23 OncoSec reports Type C meeting with FDA for melanoma treatment 05/15/23 Canadian Solar subsidiary signs aggregation deal for 100MW in Texas LPTX Leap Therapeutics / + 04/12/23 Leap Therapeutics completes enrollment in Part A of DeFianCe study of DKN-01 03/16/23 Leap Therapeutics provides update on BeiGene option agreement for DKN-01 01/17/23 Leap Therapeutics acquires Flame Biosciences INCY Incyte $65.11 / +0.715 (+1.11%) 05/02/23 Incyte tightens Jakafi net product revenues view $2.55B - $2.63B 05/01/23 Incyte says SCRATCH-AD trial meets primary endpoint 04/20/23 Incyte reports EC approval of Opzelura for non-segmental vitiligo repigmentation 04/16/23 MorphoSys, Incyte announce five-year follow-up data from Phase 2 L-MIND study IMRX Immuneering $6.95 / -1.23 (-15.04%) 04/18/23 Immuneering down 5% at $11.53 after pricing $30M stock offering 04/18/23 Immuneering announces initial Phase 1 PK, PD, safety data for IMM-1-104 03/28/23 Immuneering appoints Harold Brakewood as CBO 03/05/23 Immuneering presents preclinical data with lead program IMM-1-104 ERAS Erasca $3.00 / +0.075 (+2.57%) 05/16/23 Erasca appoints Davd Chacko as CBO, Nik Chetwyn as COO 05/01/23 Erasca announces U.S. FDA granted FTD to ERAS-801 04/25/23 Erasca announces publication of clinical data on naporafenib 04/18/23 Erasca presents Phase 1b dose escalation data from FLAGSHIP-1 for ERAS-601 EFTR eFfector Therapeutics / + 04/11/23 eFfector Therapeutics to collaborate with Standford Medicine 02/21/23 eFfector announces top-line results from Phase 1b trial of zotatifin 01/05/23 eFfector Therapeutics provides clinical data update for Zotatifin CRVS Corvus Pharmaceuticals $3.09 / -0.28 (-8.31%) 05/17/23 Corvus Pharmaceuticals to present new CPI-818 data at ICML meeting 04/17/23 Corvus Pharmaceuticals presents new data for CPI-818 04/03/23 Corvus Pharmaceuticals announces interim data on CPI-818 02/21/23 Corvus Pharmaceuticals announces new data on CPI-818 ERAS IMRX VSTM MRK INCY EFTR LPTX RCUS CRVS ERAS Erasca $3.00 / +0.075 (+2.57%) 03/29/23 Mizuho Erasca initiated with a Buy at Mizuho 02/24/23 Goldman Sachs Erasca initiated with a Buy at Goldman Sachs 02/03/23 Morgan Stanley Erasca upgraded to Overweight from Equal Weight at Morgan Stanley IMRX Immuneering $6.95 / -1.23 (-15.04%) 04/19/23 Mizuho Immuneering upgraded to Buy from Neutral at Mizuho 04/19/23 Morgan Stanley Immuneering upgraded to Equal Weight from Underweight at Morgan Stanley 04/18/23 Chardan Immuneering price target raised to $22 from $18 at Chardan 03/29/23 Mizuho Immuneering initiated with a Neutral at Mizuho VSTM Verastem / + 05/10/23 H.C. Wainwright Verastem price target lowered to $2 from $3 at H.C. Wainwright 03/29/23 Mizuho Verastem initiated with a Neutral at Mizuho 11/07/22 H.C. Wainwright Verastem price target lowered to $3 from $5 at H.C. Wainwright 10/05/22 BTIG Verastem price target lowered to $5 from $8 at BTIG MRK Merck $113.28 / -1.175 (-1.03%) 05/10/23 Jefferies Prometheus downgraded to Hold from Buy at Jefferies 05/01/23 Barclays Merck price target raised to $130 from $128 at Barclays 04/18/23 Wells Fargo Prometheus downgraded to Equal Weight from Overweight at Wells Fargo 04/18/23 RBC Capital Prometheus downgraded to Sector Perform from Outperform at RBC Capital INCY Incyte $65.11 / +0.715 (+1.11%) 05/04/23 JMP Securities Incyte price target lowered to $93 from $113 at JMP Securities 05/04/23 BofA Incyte downgraded to Neutral at BofA on long-term value uncertainty 05/04/23 BofA Incyte downgraded to Neutral from Buy at BofA 05/03/23 BMO Capital Incyte price target lowered to $70 from $75 at BMO Capital EFTR eFfector Therapeutics / + LPTX Leap Therapeutics / + 03/17/23 Piper Sandler Leap Therapeutics news 'disappointing at first glance,' says Piper Sandler 03/17/23 Mizuho Leap Therapeutics price target lowered to $2 from $3 at Mizuho 01/27/23 Mizuho Leap Therapeutics price target lowered to $3 from $6 at Mizuho 01/17/23 Piper Sandler Leap Therapeutics price target lowered to $3 from $4 at Piper Sandler RCUS Arcus Biosciences $18.06 / -0.08 (-0.44%) 03/09/23 Citi Arcus Biosciences price target lowered to $40 from $42 at Citi 12/21/22 Citi Arcus Biosciences selloff a buying opportunity, says Citi 12/21/22 Barclays Arcus Biosciences price target lowered to $36 from $60 at Barclays 12/20/22 Citi Arcus Biosciences price target raised to $42 from $37 at Citi CRVS Corvus Pharmaceuticals $3.09 / -0.28 (-8.31%) 05/09/23 Cantor Fitzgerald Corvus Pharmaceuticals price target raised to $4 from $2 at Cantor Fitzgerald 10/07/22 Ladenburg Corvus Pharmaceuticals initiated with a Buy at Ladenburg 08/09/22 Cantor Fitzgerald Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald VSTM RCUS MRK LPTX INCY ERAS EFTR CRVS VSTM Verastem / + 05/09/23 Verastem reports Q1 EPS (9c), consensus (8c) 03/14/23 Verastem reports Q4 EPS (8c), consensus (10c) RCUS Arcus Biosciences $18.06 / -0.08 (-0.44%) 05/09/23 Arcus Biosciences reports Q1 EPS ($1.09), consensus ($1.16) 02/28/23 Arcus Biosciences reports Q4 EPS (93c), consensus ($1.07) MRK Merck $113.28 / -1.175 (-1.03%) 04/27/23 Merck narrows FY23 revenue view to $57.7B-$58.9B from $57.2B-$58.7B 04/27/23 Merck reports Q1 adjusted EPS $1.40, consensus $1.32 04/26/23 Notable companies reporting before tomorrow's open LPTX Leap Therapeutics / + 05/15/23 Leap Therapeutics reports Q1 EPS (32c), consensus (10c) 03/24/23 Leap Therapeutics reports Q4 EPS (11c), consensus (11c) INCY Incyte $65.11 / +0.715 (+1.11%) 05/02/23 Incyte reports Q1 EPS 37c, consensus 75c 02/07/23 Incyte reports Q4 EPS 62c, consensus 58c 02/06/23 Notable companies reporting before tomorrow's open ERAS Erasca $3.00 / +0.075 (+2.57%) 05/15/23 Erasca reports Q1 EPS (22c), consensus (31c) 03/23/23 Erasca reports Q4 EPS ($1.06) vs. (26c) last year EFTR eFfector Therapeutics / + 05/09/23 eFfector Therapeutics reports Q1 EPS (24c), consensus (14c) 03/08/23 eFfector Therapeutics reports Q4 EPS (22c), consensus (24c) CRVS Corvus Pharmaceuticals $3.09 / -0.28 (-8.31%) 05/08/23 Corvus Pharmaceuticals reports Q1 EPS (17c), consensus (16c) 18 Apr 09 Dec MRK MRK Merck $113.28 / -1.175 (-1.03%) 02/27/23 Pfizer in talks to buy Seagen in deal that may be valued at over $30B, WSJ says 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 01/11/23 Merck, Pfizer rebuff China's efforts to cut Covid drug prices, Bloomberg says 12/30/22 Merck's Covid treatment gets conditional approval in China, Reuters reports VSTM RCUS MRK LPTX INCY ERAS VSTM Verastem / + 03/14/23 Fly Intel: After-Hours Movers RCUS Arcus Biosciences $18.06 / -0.08 (-0.44%) 12/20/22 What You Missed On Wall Street On Tuesday 12/20/22 What You Missed On Wall Street This Morning 12/19/22 Fly Intel: After-Hours Movers 11/30/22 Biotech Alert: Searches spiking for these stocks today MRK Merck $113.28 / -1.175 (-1.03%) 05/16/23 What You Missed On Wall Street On Tuesday 04/27/23 Fly Intel: Pre-market Movers 04/19/23 Biotech Alert: Searches spiking for these stocks today 04/17/23 What You Missed On Wall Street On Monday LPTX Leap Therapeutics / + 05/19/23 Biotech Alert: Searches spiking for these stocks today 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning INCY Incyte $65.11 / +0.715 (+1.11%) 05/05/23 Biotech Alert: Searches spiking for these stocks today 05/04/23 Biotech Alert: Searches spiking for these stocks today 05/02/23 Fly Intel: Pre-market Movers 04/10/23 What You Missed On Wall Street On Monday ERAS Erasca $3.00 / +0.075 (+2.57%) 03/23/23 Fly Intel: After-Hours Movers 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning 05/24/23 Biotechnology 06/02/23 Biotechnology--Pre-ASCO Reception 06/09/23 Biotechnology 06/12/23 Biotech/Biopharma 06/06/23 2023 ASCO Annual Meeting 05/31/23 Verastem - VSTM 08/01/23 Merck - MRK 05/24/23 Immuneering 06/14/23 Incyte Corporation 06/14/23 Immuneering Corp. 06/15/23 Arcus Biosciences, Inc. 06/15/23 Corvus Pharmaceuticals, Inc. 06/16/23 Leap Therapeutics, Inc. 06/22/23 Erasca, Inc. 06/22/23 eFFECTOR Therapeutics Inc MRK MRK Merck $113.28 / -1.175 (-1.03%) 04/25/23 Merck call volume above normal and directionally bullish 04/17/23 Unusually active option classes on open April 17th 03/10/23 Early notable gainers among liquid option names on March 10th 01/10/23 Largest borrow rate increases among liquid names

Over a week ago
Conference/Events	Mizuho biotech analyst to hold an analyst/industry conference call » 16:33 05/18/23 05/18 16:33 05/18/23 16:33 ERAS Erasca $2.76 / -0.14 (-4.84%) , IMRX Immuneering $8.90 / +0.25 (+2.89%) , VSTM Verastem / + , MRK Merck $114.03 / -0.75 (-0.65%) , INCY Incyte $63.61 / -0.92 (-1.43%) , EFTR eFfector Therapeutics / + , LPTX Leap Therapeutics / + , RCUS Arcus Biosciences $17.63 / -0.51 (-2.81%) , CRVS Corvus Pharmaceuticals $3.25 / +0.01 (+0.31%) Biotechnology Analyst… Biotechnology Analyst Goldstein, along with Drs. Velcheti and Oberstein discuss targeted therapies in lung and GI cancer, (ERAS, IMRX, VSTM, MRK, INCY, EFTR, LPTX, RCUS, CRVS) as well as emerging trends and themes to be covered at the upcoming ASCO 2023 Annual Meeting on an Analyst/Industry conference call to be held on May 24 at 10 am. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VSTM RCUS MRK LPTX INCY IMRX ERAS EFTR CRVS VSTM Verastem / + 04/26/23 Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO 01/24/23 Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study RCUS Arcus Biosciences $17.63 / -0.51 (-2.81%) 05/15/23 Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead 05/15/23 Expanded Gilead- Arcus pact may result in up to $1B in payments to Arcus 05/15/23 Arcus to receive upfront payment of $35M from Gilead in expanded research pact 12/20/22 Arcus Biosciences falls -30.2% MRK Merck $114.03 / -0.75 (-0.65%) 05/17/23 Immutep announces results from Phse II TACTI-002 trial 05/16/23 Prometheus, Seagen slip after FTC sues to block Horizon acquisition 05/16/23 OncoSec reports Type C meeting with FDA for melanoma treatment 05/15/23 Canadian Solar subsidiary signs aggregation deal for 100MW in Texas LPTX Leap Therapeutics / + 04/12/23 Leap Therapeutics completes enrollment in Part A of DeFianCe study of DKN-01 03/16/23 Leap Therapeutics provides update on BeiGene option agreement for DKN-01 01/17/23 Leap Therapeutics acquires Flame Biosciences INCY Incyte $63.61 / -0.92 (-1.43%) 05/02/23 Incyte tightens Jakafi net product revenues view $2.55B - $2.63B 05/01/23 Incyte says SCRATCH-AD trial meets primary endpoint 04/20/23 Incyte reports EC approval of Opzelura for non-segmental vitiligo repigmentation 04/16/23 MorphoSys, Incyte announce five-year follow-up data from Phase 2 L-MIND study IMRX Immuneering $8.90 / +0.25 (+2.89%) 04/18/23 Immuneering down 5% at $11.53 after pricing $30M stock offering 04/18/23 Immuneering announces initial Phase 1 PK, PD, safety data for IMM-1-104 03/28/23 Immuneering appoints Harold Brakewood as CBO 03/05/23 Immuneering presents preclinical data with lead program IMM-1-104 ERAS Erasca $2.76 / -0.14 (-4.84%) 05/16/23 Erasca appoints Davd Chacko as CBO, Nik Chetwyn as COO 05/01/23 Erasca announces U.S. FDA granted FTD to ERAS-801 04/25/23 Erasca announces publication of clinical data on naporafenib 04/18/23 Erasca presents Phase 1b dose escalation data from FLAGSHIP-1 for ERAS-601 EFTR eFfector Therapeutics / + 04/11/23 eFfector Therapeutics to collaborate with Standford Medicine 02/21/23 eFfector announces top-line results from Phase 1b trial of zotatifin 01/05/23 eFfector Therapeutics provides clinical data update for Zotatifin CRVS Corvus Pharmaceuticals $3.25 / +0.01 (+0.31%) 05/17/23 Corvus Pharmaceuticals to present new CPI-818 data at ICML meeting 04/17/23 Corvus Pharmaceuticals presents new data for CPI-818 04/03/23 Corvus Pharmaceuticals announces interim data on CPI-818 02/21/23 Corvus Pharmaceuticals announces new data on CPI-818 ERAS IMRX VSTM MRK INCY EFTR LPTX RCUS CRVS ERAS Erasca $2.76 / -0.14 (-4.84%) 03/29/23 Mizuho Erasca initiated with a Buy at Mizuho 02/24/23 Goldman Sachs Erasca initiated with a Buy at Goldman Sachs 02/03/23 Morgan Stanley Erasca upgraded to Overweight from Equal Weight at Morgan Stanley IMRX Immuneering $8.90 / +0.25 (+2.89%) 04/19/23 Mizuho Immuneering upgraded to Buy from Neutral at Mizuho 04/19/23 Morgan Stanley Immuneering upgraded to Equal Weight from Underweight at Morgan Stanley 04/18/23 Chardan Immuneering price target raised to $22 from $18 at Chardan 03/29/23 Mizuho Immuneering initiated with a Neutral at Mizuho VSTM Verastem / + 05/10/23 H.C. Wainwright Verastem price target lowered to $2 from $3 at H.C. Wainwright 03/29/23 Mizuho Verastem initiated with a Neutral at Mizuho 11/07/22 H.C. Wainwright Verastem price target lowered to $3 from $5 at H.C. Wainwright 10/05/22 BTIG Verastem price target lowered to $5 from $8 at BTIG MRK Merck $114.03 / -0.75 (-0.65%) 05/10/23 Jefferies Prometheus downgraded to Hold from Buy at Jefferies 05/01/23 Barclays Merck price target raised to $130 from $128 at Barclays 04/18/23 Wells Fargo Prometheus downgraded to Equal Weight from Overweight at Wells Fargo 04/18/23 RBC Capital Prometheus downgraded to Sector Perform from Outperform at RBC Capital INCY Incyte $63.61 / -0.92 (-1.43%) 05/04/23 JMP Securities Incyte price target lowered to $93 from $113 at JMP Securities 05/04/23 BofA Incyte downgraded to Neutral at BofA on long-term value uncertainty 05/04/23 BofA Incyte downgraded to Neutral from Buy at BofA 05/03/23 BMO Capital Incyte price target lowered to $70 from $75 at BMO Capital EFTR eFfector Therapeutics / + LPTX Leap Therapeutics / + 03/17/23 Piper Sandler Leap Therapeutics news 'disappointing at first glance,' says Piper Sandler 03/17/23 Mizuho Leap Therapeutics price target lowered to $2 from $3 at Mizuho 01/27/23 Mizuho Leap Therapeutics price target lowered to $3 from $6 at Mizuho 01/17/23 Piper Sandler Leap Therapeutics price target lowered to $3 from $4 at Piper Sandler RCUS Arcus Biosciences $17.63 / -0.51 (-2.81%) 03/09/23 Citi Arcus Biosciences price target lowered to $40 from $42 at Citi 12/21/22 Citi Arcus Biosciences selloff a buying opportunity, says Citi 12/21/22 Barclays Arcus Biosciences price target lowered to $36 from $60 at Barclays 12/20/22 Citi Arcus Biosciences price target raised to $42 from $37 at Citi CRVS Corvus Pharmaceuticals $3.25 / +0.01 (+0.31%) 05/09/23 Cantor Fitzgerald Corvus Pharmaceuticals price target raised to $4 from $2 at Cantor Fitzgerald 10/07/22 Ladenburg Corvus Pharmaceuticals initiated with a Buy at Ladenburg 08/09/22 Cantor Fitzgerald Corvus Pharmaceuticals price target lowered to $4 from $8 at Cantor Fitzgerald VSTM RCUS MRK LPTX INCY ERAS EFTR CRVS VSTM Verastem / + 05/09/23 Verastem reports Q1 EPS (9c), consensus (8c) 03/14/23 Verastem reports Q4 EPS (8c), consensus (10c) RCUS Arcus Biosciences $17.63 / -0.51 (-2.81%) 05/09/23 Arcus Biosciences reports Q1 EPS ($1.09), consensus ($1.16) 02/28/23 Arcus Biosciences reports Q4 EPS (93c), consensus ($1.07) MRK Merck $114.03 / -0.75 (-0.65%) 04/27/23 Merck narrows FY23 revenue view to $57.7B-$58.9B from $57.2B-$58.7B 04/27/23 Merck reports Q1 adjusted EPS $1.40, consensus $1.32 04/26/23 Notable companies reporting before tomorrow's open LPTX Leap Therapeutics / + 05/15/23 Leap Therapeutics reports Q1 EPS (32c), consensus (10c) 03/24/23 Leap Therapeutics reports Q4 EPS (11c), consensus (11c) INCY Incyte $63.61 / -0.92 (-1.43%) 05/02/23 Incyte reports Q1 EPS 37c, consensus 75c 02/07/23 Incyte reports Q4 EPS 62c, consensus 58c 02/06/23 Notable companies reporting before tomorrow's open ERAS Erasca $2.76 / -0.14 (-4.84%) 05/15/23 Erasca reports Q1 EPS (22c), consensus (31c) 03/23/23 Erasca reports Q4 EPS ($1.06) vs. (26c) last year EFTR eFfector Therapeutics / + 05/09/23 eFfector Therapeutics reports Q1 EPS (24c), consensus (14c) 03/08/23 eFfector Therapeutics reports Q4 EPS (22c), consensus (24c) CRVS Corvus Pharmaceuticals $3.25 / +0.01 (+0.31%) 05/08/23 Corvus Pharmaceuticals reports Q1 EPS (17c), consensus (16c) 18 Apr 09 Dec MRK MRK Merck $114.03 / -0.75 (-0.65%) 02/27/23 Pfizer in talks to buy Seagen in deal that may be valued at over $30B, WSJ says 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 01/11/23 Merck, Pfizer rebuff China's efforts to cut Covid drug prices, Bloomberg says 12/30/22 Merck's Covid treatment gets conditional approval in China, Reuters reports VSTM RCUS MRK LPTX INCY ERAS VSTM Verastem / + 03/14/23 Fly Intel: After-Hours Movers RCUS Arcus Biosciences $17.63 / -0.51 (-2.81%) 12/20/22 What You Missed On Wall Street On Tuesday 12/20/22 What You Missed On Wall Street This Morning 12/19/22 Fly Intel: After-Hours Movers 11/30/22 Biotech Alert: Searches spiking for these stocks today MRK Merck $114.03 / -0.75 (-0.65%) 05/16/23 What You Missed On Wall Street On Tuesday 04/27/23 Fly Intel: Pre-market Movers 04/19/23 Biotech Alert: Searches spiking for these stocks today 04/17/23 What You Missed On Wall Street On Monday LPTX Leap Therapeutics / + 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning INCY Incyte $63.61 / -0.92 (-1.43%) 05/05/23 Biotech Alert: Searches spiking for these stocks today 05/04/23 Biotech Alert: Searches spiking for these stocks today 05/02/23 Fly Intel: Pre-market Movers 04/10/23 What You Missed On Wall Street On Monday ERAS Erasca $2.76 / -0.14 (-4.84%) 03/23/23 Fly Intel: After-Hours Movers 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/09/22 What You Missed On Wall Street On Friday 12/09/22 What You Missed On Wall Street This Morning 05/19/23 ATS 2023 International Conference 08/01/23 Merck - MRK 05/23/23 Immuneering 05/23/23 Merck & Co. Inc. 05/24/23 Immuneering 06/14/23 Incyte Corporation 06/14/23 Immuneering Corp. 06/15/23 Arcus Biosciences, Inc. 06/15/23 Corvus Pharmaceuticals, Inc. 06/16/23 Leap Therapeutics, Inc. 06/22/23 Erasca, Inc. 06/22/23 eFFECTOR Therapeutics Inc MRK MRK Merck $114.03 / -0.75 (-0.65%) 04/25/23 Merck call volume above normal and directionally bullish 04/17/23 Unusually active option classes on open April 17th 03/10/23 Early notable gainers among liquid option names on March 10th 01/10/23 Largest borrow rate increases among liquid names
On The Fly	Biotech Alert: Searches spiking for these stocks today » 11:10 05/05/23 05/05 11:10 05/05/23 11:10 LXRX Lexicon $3.30 / +0.215 (+6.98%) , MEIP MEI Pharma $6.35 / -0.05 (-0.78%) , INCY Incyte $66.07 / -0.115 (-0.17%) , ITCI Intra-Cellular $62.99 / +0.86 (+1.38%) , AQST Aquestive Therapeutics $2.18 / +0.215 (+10.94%) These names in the… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events MEIP LXRX ITCI INCY AQST MEIP MEI Pharma $6.35 / -0.05 (-0.78%) 04/14/23 MEI Pharma announces 1-for-20 reverse stock split 02/23/23 MEI, Infinity report all-stock transaction to advance three oncology candidates 12/05/22 MEI Pharma announces 30% workforce reduction 12/05/22 MEI Pharma announces realignment of clinical development efforts LXRX Lexicon $3.30 / +0.215 (+6.98%) 04/21/23 Lexicon to present results from results from RELIEF-PHN-1 trial of LX9211 03/05/23 Lexicon announces analyses of results from SOLOIST-WHF Phase 3 outcomes study 12/21/22 Lexicon announces results from proof-of-concept study of LX9211 for neuralgia 11/14/22 Lexicon presents full results from RELIEF-DPN-1 trial ITCI Intra-Cellular $62.99 / +0.86 (+1.38%) 03/28/23 Intra-Cellular: Study 403 of lumateperone met primary endpoint for MDD 02/23/23 FFJ short Intra-Cellular, says users reporting 'particularly toxic side effect' 12/08/22 Intra-Cellular highlights CAPLYRA bipolar depression data INCY Incyte $66.07 / -0.115 (-0.17%) 05/02/23 Incyte tightens Jakafi net product revenues view $2.55B - $2.63B 05/01/23 Incyte says SCRATCH-AD trial meets primary endpoint 04/20/23 Incyte reports EC approval of Opzelura for non-segmental vitiligo repigmentation 04/16/23 MorphoSys, Incyte announce five-year follow-up data from Phase 2 L-MIND study AQST Aquestive Therapeutics $2.18 / +0.215 (+10.94%) 04/20/23 Aquestive receives conditional FDA acceptance for name for AQST-109 03/29/23 Aquestive Therapeutics expands license, supply agreement with Pharmanovia 01/06/23 Aquestive Therapeutics provides business update, 2023 objectives 12/22/22 Aquestive Therapeutics completes FDA End-of-Phase 2 meeting for AQST-109 LXRX MEIP INCY ITCI AQST LXRX Lexicon $3.30 / +0.215 (+6.98%) 03/07/23 Jefferies Lexicon initiated with a Hold at Jefferies 10/03/22 Piper Sandler Lexicon remains 'significantly undervalued,' says Piper Sandler 08/29/22 Citi AstraZeneca hazard ratio notably weaker than Lexicon, says Citi 08/12/22 Piper Sandler Lexicon initiated with an Overweight at Piper Sandler MEIP MEI Pharma $6.35 / -0.05 (-0.78%) 02/24/23 Piper Sandler Infinity Pharmaceuticals downgraded to Neutral from Overweight at Piper Sandler 02/13/23 H.C. Wainwright MEI Pharma price target lowered to $2 from $5 at H.C. Wainwright 02/08/23 Jefferies MEI Pharma downgraded to Underperform from Hold at Jefferies 12/06/22 Truist MEI Pharma cut to Hold at Truist after decision to discontinue zandelisib INCY Incyte $66.07 / -0.115 (-0.17%) 05/04/23 JMP Securities Incyte price target lowered to $93 from $113 at JMP Securities 05/04/23 BofA Incyte downgraded to Neutral at BofA on long-term value uncertainty 05/04/23 BofA Incyte downgraded to Neutral from Buy at BofA 05/03/23 BMO Capital Incyte price target lowered to $70 from $75 at BMO Capital ITCI Intra-Cellular $62.99 / +0.86 (+1.38%) 05/05/23 Cantor Fitzgerald Intra-Cellular price target raised to $90 from $87 at Cantor Fitzgerald 04/20/23 Morgan Stanley Intra-Cellular initiated with an Overweight at Morgan Stanley 03/29/23 Cantor Fitzgerald Intra-Cellular price target raised to $87 from $83 at Cantor Fitzgerald 03/29/23 BofA Intra-Cellular price target raised to $63 from $62 at BofA AQST Aquestive Therapeutics $2.18 / +0.215 (+10.94%) 03/09/23 Wedbush Aquestive Therapeutics upgraded at Wedbush with cash runway extended 03/09/23 Wedbush Aquestive Therapeutics upgraded to Outperform from Neutral at Wedbush 01/31/23 Wedbush Aquestive Therapeutics downgraded to Neutral from Outperform at Wedbush 11/04/22 Alliance Global Partners Aquestive price target lowered to $7 from $10 at Alliance Global Partners MEIP LXRX ITCI INCY AQST MEIP MEI Pharma $6.35 / -0.05 (-0.78%) 02/09/23 MEI Pharma reports Q2 EPS 8c, consensus (14c) 11/14/22 MEI Pharma reports Q1 EPS (12c), consensus (14c) LXRX Lexicon $3.30 / +0.215 (+6.98%) 05/02/23 Lexicon reports Q1 EPS (17c), consensus (18c) 03/02/23 Lexicon reports Q4 EPS (16c), consensus (13c) 11/09/22 Lexicon reports Q3 EPS (13c), consensus (14c) ITCI Intra-Cellular $62.99 / +0.86 (+1.38%) 05/04/23 Intra-Cellular reiterating FY23 including CAPLYTA revenue $430M-$445M 05/04/23 Intra-Cellular reports Q1 EPS (46c), consensus (60c) 03/01/23 Intra-Cellular reports Q4 EPS (45c), consensus (59c) INCY Incyte $66.07 / -0.115 (-0.17%) 05/02/23 Incyte reports Q1 EPS 37c, consensus 75c 02/07/23 Incyte reports Q4 EPS 62c, consensus 58c 02/06/23 Notable companies reporting before tomorrow's open AQST Aquestive Therapeutics $2.18 / +0.215 (+10.94%) 03/07/23 Aquestive Therapeutics sees FY23 revenue $37M-$41M, consensus $37.83M 03/07/23 Aquestive Therapeutics reports Q4 EPS (23c), consensus (23c) MEIP ITCI INCY MEIP MEI Pharma $6.35 / -0.05 (-0.78%) 12/06/22 Fly Intel: Pre-market Movers ITCI Intra-Cellular $62.99 / +0.86 (+1.38%) 04/03/23 Fly Insider: Kohl's, 89Bio among week's notable insider trades 03/31/23 Biotech Alert: Searches spiking for these stocks today INCY Incyte $66.07 / -0.115 (-0.17%) 05/04/23 Biotech Alert: Searches spiking for these stocks today 05/02/23 Fly Intel: Pre-market Movers 04/10/23 What You Missed On Wall Street On Monday 04/10/23 What You Missed On Wall Street This Morning 05/19/23 ATS 2023 International Conference 05/27/23 PDUFA Date for Sotagliflozin 06/14/23 Incyte Corporation 06/21/23 Aquestive Therapeutics, Inc. 06/23/23 Intra-Cellular Therapies, Inc.
On The Fly	Biotech Alert: Searches spiking for these stocks today » 11:07 05/04/23 05/04 11:07 05/04/23 11:07 CABA Cabaletta Bio $11.74 / -0.515 (-4.20%) , INCY Incyte $66.73 / -1.295 (-1.90%) , EYEN Eyenovia $5.31 / -0.45 (-7.81%) , TGTX TG Therapeutics $33.78 / -1.105 (-3.17%) , ASND Ascendis Pharma $92.93 / +1.42 (+1.55%) These names in the… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options TGTX INCY EYEN CABA ASND TGTX TG Therapeutics $33.78 / -1.105 (-3.17%) 04/27/23 TG Therapeutics announces issuance of permanent J-code for BRIUMVI 04/25/23 TG Therapeutics to present data from ULTIMATE I & II Phase 3 trials of BRIUMVI 03/31/23 TG Therapeutics announces positive CHMP opinion for BRIUMVI 01/26/23 TG Therapeutics announces commercial launch of BRIUMVI INCY Incyte $66.73 / -1.295 (-1.90%) 05/02/23 Incyte tightens Jakafi net product revenues view $2.55B - $2.63B 05/01/23 Incyte says SCRATCH-AD trial meets primary endpoint 04/20/23 Incyte reports EC approval of Opzelura for non-segmental vitiligo repigmentation 04/16/23 MorphoSys, Incyte announce five-year follow-up data from Phase 2 L-MIND study EYEN Eyenovia $5.31 / -0.45 (-7.81%) 04/24/23 Eyenovia announces poster presentation Optejet at ARVO 2023 02/15/23 Eyenovia announces development collaboration agreement with Formosa 01/12/23 Eyenovia shares evidence that Optejet delivery technology decreased inflamation 12/20/22 Eyenovia to participate at 2023 International Consumers Electronics Show CABA Cabaletta Bio $11.74 / -0.515 (-4.20%) 05/01/23 Cabaletta Bio receives FDA Fast Track Designation for CABA-201 03/31/23 Cabaletta Bio receives FDA clearance of IND application for CABA-201 01/09/23 Autolus enters non-exclusive license agreement with Cabaletta 12/08/22 Cabaletta Bio announces $35M offering ASND Ascendis Pharma $92.93 / +1.42 (+1.55%) 05/01/23 Ascendis Pharma receives FDA CRL for TransCon PTH in hypoparathyroidism 04/03/23 Ascendis Pharma falls 38% after disclosing FDA notice of deficiencies in NDA 04/03/23 Ascendis' Phase 1/2 initial trial results of TransCon accepted for ASCO 2023 04/03/23 Ascendis announces FDA notified it of deficiencies in NDA for TransCon PTH CABA INCY EYEN TGTX ASND CABA Cabaletta Bio $11.74 / -0.515 (-4.20%) 03/17/23 H.C. Wainwright Cabaletta Bio price target raised to $15 from $11 at H.C. Wainwright 02/16/23 Evercore ISI Cabaletta Bio price target raised to $18 from $14 at Evercore ISI 01/27/23 Morgan Stanley Morgan Stanley upgrades Cabaletta Bio ahead of new drug filing 01/27/23 Morgan Stanley Cabaletta Bio upgraded to Overweight from Equal Weight at Morgan Stanley INCY Incyte $66.73 / -1.295 (-1.90%) 05/04/23 JMP Securities Incyte price target lowered to $93 from $113 at JMP Securities 05/04/23 BofA Incyte downgraded to Neutral at BofA on long-term value uncertainty 05/04/23 BofA Incyte downgraded to Neutral from Buy at BofA 05/03/23 BMO Capital Incyte price target lowered to $70 from $75 at BMO Capital EYEN Eyenovia $5.31 / -0.45 (-7.81%) 10/05/22 H.C. Wainwright Eyenovia initiated with a Buy at H.C. Wainwright TGTX TG Therapeutics $33.78 / -1.105 (-3.17%) 05/02/23 JPMorgan TG Therapeutics price target raised to $34 from $28 at JPMorgan 05/02/23 Ladenburg TG Therapeutics price target raised to $37.50 from $26 at Ladenburg 05/01/23 H.C. Wainwright TG Therapeutics price target raised to $34 from $28 at H.C. Wainwright 04/25/23 Cantor Fitzgerald Cantor thinks M&A premium 'baked into' TG Therapeutics shares will increase ASND Ascendis Pharma $92.93 / +1.42 (+1.55%) 04/28/23 Cantor Fitzgerald Ascendis Pharma price target raised to $152 from $142 at Cantor Fitzgerald 04/12/23 Morgan Stanley Ascendis Pharma price target lowered to $107 from $108 at Morgan Stanley 04/05/23 Oppenheimer Ascendis Pharma downgraded to Perform Oppenheimer ahead of likely CRL 04/05/23 Citi Citi cuts Ascendis Pharma target, removes from Focus List TGTX INCY EYEN CABA TGTX TG Therapeutics $33.78 / -1.105 (-3.17%) 05/01/23 TG Therapeutics reports Q1 EPS (28c), consensus (37c) 02/28/23 TG Therapeutics reports Q4 EPS (39c), consensus (26c) 11/10/22 TG Therapeutics reports Q3 EPS (26c), consensus (39c) INCY Incyte $66.73 / -1.295 (-1.90%) 05/02/23 Incyte reports Q1 EPS 37c, consensus 75c 02/07/23 Incyte reports Q4 EPS 62c, consensus 58c 02/06/23 Notable companies reporting before tomorrow's open EYEN Eyenovia $5.31 / -0.45 (-7.81%) 11/10/22 Eyenovia reports Q3 EPS (21c), consensus (20c) CABA Cabaletta Bio $11.74 / -0.515 (-4.20%) 03/16/23 Cabaletta Bio reports Q4 EPS (52c), consensus (45c) 11/10/22 Cabaletta Bio reports Q3 EPS (39c), consensus (48c) TGTX INCY ASND TGTX TG Therapeutics $33.78 / -1.105 (-3.17%) 05/03/23 Biotech Alert: Searches spiking for these stocks today 04/14/23 Biotech Alert: Searches spiking for these stocks today 04/12/23 Biotech Alert: Searches spiking for these stocks today 01/24/23 What You Missed On Wall Street On Tuesday INCY Incyte $66.73 / -1.295 (-1.90%) 05/02/23 Fly Intel: Pre-market Movers 04/10/23 What You Missed On Wall Street On Monday 04/10/23 What You Missed On Wall Street This Morning 04/10/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ASND Ascendis Pharma $92.93 / +1.42 (+1.55%) 04/06/23 Biotech Alert: Searches spiking for these stocks today 04/05/23 Biotech Alert: Searches spiking for these stocks today 04/05/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/19/23 ATS 2023 International Conference 05/11/23 Eyenovia - EYEN 06/01/23 Cabaletta Bio, Inc. 06/14/23 TG Therapeutics, Inc. 06/14/23 Incyte Corporation TGTX EYEN TGTX TG Therapeutics $33.78 / -1.105 (-3.17%) 04/25/23 TG Therapeutics call volume above normal and directionally bullish 02/27/23 TG Therapeutics options imply 4.1% move in share price post-earnings 02/16/23 TG Therapeutics call volume above normal and directionally bullish 02/13/23 TG Therapeutics call buyer realizes 91% same-day gains EYEN Eyenovia $5.31 / -0.45 (-7.81%) 04/17/23 Three new option listings and option delistings on April 17th
Recommendations	Incyte price target lowered to $93 from $113 at JMP Securities » 06:46 05/04/23 05/04 06:46 05/04/23 06:46 INCY Incyte $68.06 / -1.9 (-2.72%) JMP Securities lowered… JMP Securities lowered the firm's price target on Incyte to $93 from $113 and keeps an Outperform rating on the shares. Despite the headwinds seen in Q1, the firm continues to believe that the underlying fundamentals of the company remain intact, and that the increasing guidance for rux revenues and decreasing GTN adjustments should impact shareholder value positively, the analyst tells investors in a research note. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events INCY Incyte $68.06 / -1.9 (-2.72%) 05/02/23 Incyte tightens Jakafi net product revenues view $2.55B - $2.63B 05/01/23 Incyte says SCRATCH-AD trial meets primary endpoint 04/20/23 Incyte reports EC approval of Opzelura for non-segmental vitiligo repigmentation 04/16/23 MorphoSys, Incyte announce five-year follow-up data from Phase 2 L-MIND study INCY Incyte $68.06 / -1.9 (-2.72%) 05/04/23 BofA Incyte downgraded to Neutral at BofA on long-term value uncertainty 05/04/23 BofA Incyte downgraded to Neutral from Buy at BofA 05/03/23 BMO Capital Incyte price target lowered to $70 from $75 at BMO Capital 05/03/23 RBC Capital Incyte price target lowered to $70 from $79 at RBC Capital INCY Incyte $68.06 / -1.9 (-2.72%) 05/02/23 Incyte reports Q1 EPS 37c, consensus 75c 02/07/23 Incyte reports Q4 EPS 62c, consensus 58c 02/06/23 Notable companies reporting before tomorrow's open INCY Incyte $68.06 / -1.9 (-2.72%) 05/02/23 Fly Intel: Pre-market Movers 04/10/23 What You Missed On Wall Street On Monday 04/10/23 What You Missed On Wall Street This Morning 04/10/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/19/23 ATS 2023 International Conference 06/14/23 Incyte Corporation
Downgrade	Incyte downgraded to Neutral at BofA on long-term value uncertainty » 06:36 05/04/23 05/04 06:36 05/04/23 06:36 INCY Incyte / + As previously reported,… As previously reported, BofA analyst Tazeen Ahmad downgraded Incyte to Neutral from Buy with a price target of $84, down from $93. A key driver of the firm's prior Buy rating had been excitement for uptake of Opzelura in skin disorders, but the firm thinks the strong initial uptake may give way to more measured growth and the firm is looking for more clarity on the long-term opportunity, the analyst tells investors. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events INCY Incyte / + 05/02/23 Incyte tightens Jakafi net product revenues view $2.55B - $2.63B 05/01/23 Incyte says SCRATCH-AD trial meets primary endpoint 04/20/23 Incyte reports EC approval of Opzelura for non-segmental vitiligo repigmentation 04/16/23 MorphoSys, Incyte announce five-year follow-up data from Phase 2 L-MIND study INCY Incyte / + 05/04/23 BofA Incyte downgraded to Neutral from Buy at BofA 05/03/23 BMO Capital Incyte price target lowered to $70 from $75 at BMO Capital 05/03/23 RBC Capital Incyte price target lowered to $70 from $79 at RBC Capital 05/03/23 TD Cowen Incyte price target lowered to $93 from $100 at TD Cowen INCY Incyte / + 05/02/23 Incyte reports Q1 EPS 37c, consensus 75c 02/07/23 Incyte reports Q4 EPS 62c, consensus 58c 02/06/23 Notable companies reporting before tomorrow's open INCY Incyte / + 05/02/23 Fly Intel: Pre-market Movers 04/10/23 What You Missed On Wall Street On Monday 04/10/23 What You Missed On Wall Street This Morning 04/10/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/19/23 ATS 2023 International Conference 06/14/23 Incyte Corporation
Downgrade	Incyte downgraded to Neutral from Buy at BofA » 06:07 05/04/23 05/04 06:07 05/04/23 06:07 INCY Incyte $68.06 / -1.9 (-2.72%) BofA downgraded Incyte to… BofA downgraded Incyte to Neutral from Buy with an $84 price target. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events INCY Incyte $68.06 / -1.9 (-2.72%) 05/02/23 Incyte tightens Jakafi net product revenues view $2.55B - $2.63B 05/01/23 Incyte says SCRATCH-AD trial meets primary endpoint 04/20/23 Incyte reports EC approval of Opzelura for non-segmental vitiligo repigmentation 04/16/23 MorphoSys, Incyte announce five-year follow-up data from Phase 2 L-MIND study INCY Incyte $68.06 / -1.9 (-2.72%) 05/03/23 BMO Capital Incyte price target lowered to $70 from $75 at BMO Capital 05/03/23 RBC Capital Incyte price target lowered to $70 from $79 at RBC Capital 05/03/23 TD Cowen Incyte price target lowered to $93 from $100 at TD Cowen 05/03/23 Stifel Incyte price target lowered to $73 from $80 at Stifel INCY Incyte $68.06 / -1.9 (-2.72%) 05/02/23 Incyte reports Q1 EPS 37c, consensus 75c 02/07/23 Incyte reports Q4 EPS 62c, consensus 58c 02/06/23 Notable companies reporting before tomorrow's open INCY Incyte $68.06 / -1.9 (-2.72%) 05/02/23 Fly Intel: Pre-market Movers 04/10/23 What You Missed On Wall Street On Monday 04/10/23 What You Missed On Wall Street This Morning 04/10/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/19/23 ATS 2023 International Conference 06/14/23 Incyte Corporation
Recommendations	Incyte price target lowered to $70 from $75 at BMO Capital » 09:54 05/03/23 05/03 09:54 05/03/23 09:54 INCY Incyte $68.95 / -1.01 (-1.44%) BMO Capital lowered the… BMO Capital lowered the firm's price target on Incyte to $70 from $75 and keeps a Market Perform rating on the shares after its Q1 earnings miss. The analyst states that with the Jakafi loss of exclusivity looming, potential impacts from Inflation Reduction Act starting to be understood and this quarter's underperformance, investors are looking for some meaningful progress out of Incyte's next generation of products. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events INCY Incyte $68.95 / -1.01 (-1.44%) 05/02/23 Incyte tightens Jakafi net product revenues view $2.55B - $2.63B 05/01/23 Incyte says SCRATCH-AD trial meets primary endpoint 04/20/23 Incyte reports EC approval of Opzelura for non-segmental vitiligo repigmentation 04/16/23 MorphoSys, Incyte announce five-year follow-up data from Phase 2 L-MIND study INCY Incyte $68.95 / -1.01 (-1.44%) 05/03/23 RBC Capital Incyte price target lowered to $70 from $79 at RBC Capital 05/03/23 TD Cowen Incyte price target lowered to $93 from $100 at TD Cowen 05/03/23 Stifel Incyte price target lowered to $73 from $80 at Stifel 05/03/23 Mizuho Incyte price target lowered to $82 from $95 at Mizuho INCY Incyte $68.95 / -1.01 (-1.44%) 05/02/23 Incyte reports Q1 EPS 37c, consensus 75c 02/07/23 Incyte reports Q4 EPS 62c, consensus 58c 02/06/23 Notable companies reporting before tomorrow's open INCY Incyte $68.95 / -1.01 (-1.44%) 05/02/23 Fly Intel: Pre-market Movers 04/10/23 What You Missed On Wall Street On Monday 04/10/23 What You Missed On Wall Street This Morning 04/10/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/19/23 ATS 2023 International Conference 06/14/23 Incyte Corporation
Recommendations	Incyte price target lowered to $70 from $79 at RBC Capital » 09:26 05/03/23 05/03 09:26 05/03/23 09:26 INCY Incyte $69.96 / -5.445 (-7.22%) RBC Capital analyst Brian… RBC Capital analyst Brian Abrahams lowered the firm's price target on Incyte to $70 from $79 and keeps a Sector Perform rating on the shares after its Q1 earnings miss. The quarter was weak primarily due to seasonal trends, but also potentially more fundamental headwinds for Opzelura, the analyst tells investors in a research note. While pipeline pruning should improve focus and longer-term operating leverage, the company also faces a high bar in the "competitive oncology spaces", RBC added. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events INCY Incyte $69.96 / -5.445 (-7.22%) 05/02/23 Incyte tightens Jakafi net product revenues view $2.55B - $2.63B 05/01/23 Incyte says SCRATCH-AD trial meets primary endpoint 04/20/23 Incyte reports EC approval of Opzelura for non-segmental vitiligo repigmentation 04/16/23 MorphoSys, Incyte announce five-year follow-up data from Phase 2 L-MIND study INCY Incyte $69.96 / -5.445 (-7.22%) 05/03/23 TD Cowen Incyte price target lowered to $93 from $100 at TD Cowen 05/03/23 Stifel Incyte price target lowered to $73 from $80 at Stifel 05/03/23 Mizuho Incyte price target lowered to $82 from $95 at Mizuho 04/12/23 Morgan Stanley Incyte price target raised to $77 from $76 at Morgan Stanley INCY Incyte $69.96 / -5.445 (-7.22%) 05/02/23 Incyte reports Q1 EPS 37c, consensus 75c 02/07/23 Incyte reports Q4 EPS 62c, consensus 58c 02/06/23 Notable companies reporting before tomorrow's open INCY Incyte $69.96 / -5.445 (-7.22%) 05/02/23 Fly Intel: Pre-market Movers 04/10/23 What You Missed On Wall Street On Monday 04/10/23 What You Missed On Wall Street This Morning 04/10/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/19/23 ATS 2023 International Conference 06/14/23 Incyte Corporation

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial